Oxford COVID-19 vaccine: Serum Institute to apply for emergency authorisation in next 2 weeks
The central government might buy 300-400 million doses of COVID-19 vaccine by July, said Poonawalla
India will be given first priority for the delivery of the AstraZeneca-Oxford vaccine, said Adar Poonawalla of SII
Serum Institute of India will apply for emergency authorisation of COVID-19 vaccine in next two weeks, the chief executive Adar Poonawalla said on Saturday. Pune based drugmaker partnered with global pharma giant AstraZeneca to produce COVID-19 vaccine by University of Oxford for low-and-middle income countries. Dubbed as Covishield, the COVID-19 vaccine is currently in the Phase III clinical trial in India.